NCT07247357

A Study of LY4064809 in Healthy Adult Chinese Participants

A Phase 1, Open-Label Study of the Pharmacokinetics of LY4064809 in Healthy Adult Chinese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 21 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to measure how much LY4064809 gets into the bloodstream and how long it takes the body to eliminate it in healthy participants. It also looks at safety and tolerability in healthy participants. The study drug will be administered orally. The study will last approximately 21 days, excluding screening.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY4064809	administered orally

Timeline

• Start date: 2025-10-24
• Primary completion: 2025-12-16
• Completion: 2025-12-16
• First posted: 2025-11-25
• Last updated: 2026-01-16

Locations

1 site across 1 country: Singapore